These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3509369)

  • 21. [The antibacterial effect of ciprofloxacin, ofloxacin and norfloxacin in vitro].
    Rotter M; Hirschl AM
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Nov; 270(1-2):145-52. PubMed ID: 3223134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
    Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
    Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current status of resistance of bacteria to pefloxacin in hospital units. Cross resistance with ofloxacin and ciprofloxacin. Results of a multicenter study].
    Thabaut A; Meyran M; Fabre R; Dellamonica P; Moreau N
    Pathol Biol (Paris); 1994 May; 42(5):369-74. PubMed ID: 7824298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Norfloxacin, ciprofloxacin, and ofloxacin: current clinical roles.
    Hooper DC; Wolfson JS
    Curr Clin Top Infect Dis; 1989; 10():194-240. PubMed ID: 2679694
    [No Abstract]   [Full Text] [Related]  

  • 25. [In vitro activity of trovafloxacin, of other fluoroquinolones and of related antimicrobials against clinical isolates. Grupo colaborativo WHONET-Argentina].
    Rossi A; Galas M; Tokumoto M; Guelfand L; Lopardo H
    Medicina (B Aires); 1999; 59 Suppl 1():8-16. PubMed ID: 10436549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of the fluoroquinolone antibiotics.
    Just PM
    Pharmacotherapy; 1993; 13(2 Pt 2):4S-17S. PubMed ID: 8386356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of ciprofloxacin in comparison with aztreonam, imipenem, and ceftazidime against multiply resistant strains.
    Nemes G; Stolle D; Nemes P
    Chemioterapia; 1987 Jun; 6(2 Suppl):133-5. PubMed ID: 3334552
    [No Abstract]   [Full Text] [Related]  

  • 28. In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates.
    Coll R; Esteve M; Moros M; Xicota MA; Parés J
    Drugs Exp Clin Res; 1987; 13(2):75-7. PubMed ID: 3582134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of standard proportion dilution test and Etest for Mycobacterium tuberculosis sensitivity to ofloxacin and ciprofloxacin].
    Cavuşoğlu C; Ciçek-Saydam C; Burhanoğlu D; Ozkalay N; Ozkaya D; Ozçam H; Bilgiç A
    Mikrobiyol Bul; 2002 Jan; 36(1):118-23. PubMed ID: 12476777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of quinolones on the faecal flora.
    Midtvedt T
    Scand J Infect Dis Suppl; 1990; 68():14-8. PubMed ID: 2218416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of antibacterial activity of norfloxacin and ofloxacin in vitro by serum and experimental pleural exudates.
    Miglioli PA; Sartore P; Gianfranceschi L; Lanzafame P; Berti T
    J Chemother; 1989 Jul; 1(4 Suppl):140-1. PubMed ID: 16312342
    [No Abstract]   [Full Text] [Related]  

  • 32. [In vitro antibacterial activity of new derivatives of pyridonecarboxylic acid, norfloxacin, ofloxacin, enoxacin and ciprofloxacin, against Vibrio cholerae O-1].
    Matsushita S; Yamada S; Kudoh Y; Ohashi M
    Kansenshogaku Zasshi; 1987 Mar; 61(3):292-6. PubMed ID: 3112282
    [No Abstract]   [Full Text] [Related]  

  • 33. Accurate characterization of ofloxacin susceptibility with Enterobacteriaceae using a modified GNS F6 card and the bioMerieux Vitek System.
    Doern GV; Torres BB; Jankins M; Jones RN
    Diagn Microbiol Infect Dis; 1996 Jul; 25(3):133-5. PubMed ID: 8902409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ofloxacin: antibacterial activity, induction of resistance and killing curves.
    Husson MO; Izard D; Bryskier A; Leclerc H
    Chemioterapia; 1985 Aug; 4(4):278-83. PubMed ID: 3863716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers.
    Zeiler HJ; Beermann D; Wingender W; Förster D; Schacht P
    Infection; 1988; 16 Suppl 1():S19-23. PubMed ID: 3286510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sensitivity of clinical bacterial strains to ofloxacin].
    Borowski J; Jakubicz P
    Pol Tyg Lek; 1990 Sep 3-10; 45(36-37):745-7. PubMed ID: 2128121
    [No Abstract]   [Full Text] [Related]  

  • 37. [Resistance against new gyrase inhibitors--1985/86].
    Shah PM; Just G; Weigand G; Stille W
    Dtsch Med Wochenschr; 1987 May; 112(22):903-4. PubMed ID: 3034545
    [No Abstract]   [Full Text] [Related]  

  • 38. Interactions between 4-quinolone antibacterials and multivalent metal ions.
    Smith JT
    J Chemother; 1989 Jul; 1(4 Suppl):134-5. PubMed ID: 16312339
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of the in vitro susceptibility and emergence of mutants resistant to ciprofloxacin among multidrug resistant clinical isolates.
    Lopes CA; Mendes RP; Curi PC; Watanabe DS; Decarlis RM; Horácio A; Michelin LA; Placidelli BA
    Rev Latinoam Microbiol; 1993; 35(4):345-9. PubMed ID: 8066328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro susceptibility of multiple drug resistant Salmonella typhimurium to newer fluroquinolone derivatives.
    Shetty M; Shivananda PG
    Indian J Pathol Microbiol; 1995 Oct; 38(4):365-8. PubMed ID: 9726145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.